Lung and blood perioperative metalloproteinases in patients undergoing oncologic lung surgery: Prognostic implications

Abstract

Abstract Background Metalloproteinases (MMPs) have been reported to be related to oncologic outcomes. The main goal of the study was to study the relationship between these proteins and the long‐term prognosis of patients undergoing oncologic lung resection surgery. Methods This was a substudy of the phase IV randomized control trial (NCT 02168751). We analyzed MMP‐2, ‐3, ‐7, and ‐9 in blood samples and bronchoalveolar lavage (LBA) and the relationship between MMPs and long postoperative outcomes (survival and disease‐free time of oncologic recurrence). Results Survival was longer in patients who had lower MMP‐2 levels than those with higher MMP‐2 in blood samples taken 6 h after surgery (6.8 vs. 5.22 years; p = 0.012) and MMP‐3 (6.82 vs. 5.35 years; p = 0.03). In contrast, survival was longer when MMP‐3 levels were higher in LBA from oncologic lung patients than those with lower MMP‐3 (7.96 vs. 6.02 years; p = 0.005). Recurrence‐free time was longer in patients who had lower MMP‐3 levels in blood samples versus higher (5.97 vs. 4.23 years; p = 0.034) as well as lower MMP‐7 (5.96 vs. 4.5 years; p = 0.041) or lower MMP‐9 in LBA samples (6.21 vs. 4.18 years; p = 0.012). Conclusion MMPs were monitored during the perioperative period of oncologic lung resection surgery. These biomarkers were associated with mortality and recurrence‐free time. The role of the different MMPs analyzed during the study do not have the same prognostic implications after this kind of surgery.

Keywords

• metalloproteinases
• oncologic lung surgery
• survival
• liquid biopsy
• oncologic disease‐free time